Contrast agents like barium and iodine, which increase the visibility of medical imaging, are suffering from a global shortage, opening the growing US$6.3 billion dollar market up to new players ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

As of December 23, 2024, the average one-year price target for Verona Pharma plc - Depositary Receipt is $47.94/share. The forecasts range from a low of $36.36 to a high of $67.20.

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 4 - 1 - 2 Manager: Kosta Runjaic ...

Verona Pharma stock opened at $45.20 on Wednesday. The business has a 50 day moving average of $41.33 and a 200-day moving average of $31.52. The company has a market capitalization of $3.64 ...

Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...